Literature DB >> 28444164

Vena contracta area for severity grading in functional and degenerative mitral regurgitation: a transoesophageal 3D colour Doppler analysis in 500 patients.

Björn Goebel1, Roland Heck1, Ali Hamadanchi1, Sylvia Otto1, Torsten Doenst2, Christian Jung3, Alexander Lauten4, Hans R Figulla1, P Christian Schulze1, Tudor C Poerner1.   

Abstract

Aims: Vena contracta area (VCA3D), derived by 3D colour Doppler echocardiography, has already been validated against cardiac magnetic resonance imaging, but the number of clinical studies to define cut-off values for grading of mitral regurgitation (MR) is limited. Aim of the study was to assess VCA3D in a large population of patients with functional (FMR) and degenerative MR (DMR). Methods and results: Transoesophageal echocardiography was performed in 500 patients with MR. The following 2D parameters were assessed for grading of MR: vena contracta width, effective regurgitant orifice area (EROAPISA), and regurgitation volume (RVPISA). VCA3D and the corresponding regurgitation volume (RVVCA) were quantified using 3D colour Doppler loop and CW Doppler tracing of the regurgitant jet. In 104 patients a 3D dataset of the left ventricle (LV) and the left ventricular outflow tract (LVOT) was acquired. As a reference method, regurgitation volume (RV3D) was calculated as difference between LV overall and LVOT stroke volumes. For prediction of severe MR, VCA3D yielded higher values of area under the ROC curve compared to EROAPISA (overall patient group 0.98 for VCA3D vs. 0.90 for EROAPISA, P < 0.001; FMR group 0.97 for VCA3D vs. 0.92 for EROAPISA, P = 0.002). RVVCA correlated closer with RV3D compared to RVPISA (r = 0.96 for RVPISA, r = 0.79 for RVPISA).
Conclusion: This study delivers cut-off values for VCA3D in patients with different types of MR. VCA3D is a robust parameter for quantification of MR, showing a good correlation with the reference method using 3D datasets of LV.

Entities:  

Mesh:

Year:  2018        PMID: 28444164     DOI: 10.1093/ehjci/jex056

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  8 in total

1.  [Evaluation of mitral regurgitation : How much quantification do we need?]

Authors:  F Kreidel; T Ruf; A Tamm; M Geyer; T Emrich; R S von Bardeleben
Journal:  Herz       Date:  2019-11       Impact factor: 1.443

Review 2.  Echocardiographic assessment of mitral regurgitation.

Authors:  Nobuyuki Kagiyama; Sirish Shrestha
Journal:  J Med Ultrason (2001)       Date:  2019-08-24       Impact factor: 1.314

Review 3.  Treatment of Functional Mitral Regurgitation in Heart Failure.

Authors:  Enrico Fabris; Antonio De Luca; Giancarlo Vitrella; Davide Stolfo; Marco Masè; Renata Korcova; Marco Merlo; Serena Rakar; Arnoud W J Van't Hof; Elvin Kedhi; Andrea Perkan; Gianfranco Sinagra
Journal:  Curr Cardiol Rep       Date:  2019-11-16       Impact factor: 2.931

Review 4.  Multimodality imaging assessment of mitral valve anatomy in planning for mitral valve repair in secondary mitral regurgitation.

Authors:  Romain Capoulade; Nicolas Piriou; Jean-Michel Serfaty; Thierry Le Tourneau
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

Review 5.  Multimodality Imaging in Secondary Mitral Regurgitation.

Authors:  Harish Sharma; Boyang Liu; Hani Mahmoud-Elsayed; Saul G Myerson; Richard P Steeds
Journal:  Front Cardiovasc Med       Date:  2020-12-22

6.  Clinical Implications of Functional Mitral Regurgitation Severity in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF).

Authors:  Nabil Naser
Journal:  Med Arch       Date:  2022-02

7.  3D vena contracta area in degenerative mitral regurgitation: cross-platform comparison in a single patient.

Authors:  Shing Ching; Chiu Sun Yue
Journal:  J Geriatr Cardiol       Date:  2022-04-28       Impact factor: 3.327

Review 8.  State-of-the-art intra-procedural imaging for the mitral and tricuspid PASCAL Repair System.

Authors:  Rebecca T Hahn; Susheel K Kodali
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2022-02-22       Impact factor: 6.875

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.